| Year |
Citation |
Score |
| 2023 |
Hailegiorgis A, Ishida Y, Collier N, Imamura M, Shi Z, Reinharz V, Tsuge M, Barash D, Hiraga N, Yokomichi H, Tateno C, Ozik J, Uprichard SL, Chayama K, Dahari H. Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics. Plos Computational Biology. 19: e1011309. PMID 37535676 DOI: 10.1371/journal.pcbi.1011309 |
0.381 |
|
| 2023 |
Maya S, Hershkovich L, Cardozo-Ojeda EF, Shirvani-Dastgerdi E, Srinivas J, Shekhtman L, Uprichard SL, Berneshawi AR, Cafiero TR, Dahari H, Ploss A. Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic. Mbio. e0100823. PMID 37436080 DOI: 10.1128/mbio.01008-23 |
0.362 |
|
| 2023 |
Maya S, Hershkovich L, Cardozo-Ojeda EF, Shirvani-Dastgerdi E, Srinivas J, Shekhtman L, Uprichard SL, Berneshawi AR, Cafiero TR, Dahari H, Ploss A. Hepatitis delta virus RNA decline post inoculation in human NTCP transgenic mice is biphasic. Biorxiv : the Preprint Server For Biology. PMID 36824865 DOI: 10.1101/2023.02.17.528964 |
0.437 |
|
| 2021 |
Shekhtman L, Navasa M, Sansone N, Crespo G, Subramanya G, Chung TL, Cardozo-Ojeda EF, Pérez-Del-Pulgar S, Perelson AS, Cotler SJ, Forns X, Uprichard SL, Dahari H. Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. Elife. 10. PMID 34730511 DOI: 10.7554/eLife.65297 |
0.59 |
|
| 2021 |
Durso-Cain K, Kumberger P, Schälte Y, Fink T, Dahari H, Hasenauer J, Uprichard SL, Graw F. HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics. Viruses. 13. PMID 34372514 DOI: 10.3390/v13071308 |
0.569 |
|
| 2021 |
Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. Journal of Virology. 95: e0049220. PMID 33910953 DOI: 10.1128/JVI.00492-20 |
0.383 |
|
| 2020 |
Etzion O, Dahari H, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Ashur Y, Uprichard SL, Arbib OS, Munteanu D, Braun M, Cotler SJ, Abufreha N, Keren-Naus A, Shemer-Avni Y, et al. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific Reports. 10: 17820. PMID 33082372 DOI: 10.1038/s41598-020-74568-x |
0.523 |
|
| 2020 |
Gorstein E, Martinello M, Churkin A, Dasgupta S, Walsh K, Applegate T, Yardeni D, Etzion O, Uprichard SL, Barash D, Cotler SJ, Matthews GV, Dahari H. Modeling based response guided therapy in subjects with recent hepatitis C infection. Antiviral Research. 104862. PMID 32592829 DOI: 10.1016/J.Antiviral.2020.104862 |
0.634 |
|
| 2020 |
Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Scientific Reports. 10: 7837. PMID 32398799 DOI: 10.1038/S41598-020-64122-0 |
0.47 |
|
| 2020 |
Dasgupta S, Imamura M, Gorstein E, Nakahara T, Tsuge M, Churkin A, Yardeni D, Etzion O, Uprichard SL, Barash D, Cotler SJ, Dahari H, Chayama K. Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration. The Journal of Infectious Diseases. PMID 32363394 DOI: 10.1093/Infdis/Jiaa219 |
0.525 |
|
| 2019 |
Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K. Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. Viruses. 11. PMID 30875937 DOI: 10.3390/V11030263 |
0.495 |
|
| 2019 |
Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Research. PMID 30711416 DOI: 10.1016/J.Antiviral.2019.01.017 |
0.65 |
|
| 2019 |
Ishida Y, Dubey P, Tsuge M, Yamao M, Tateno C, Uprichard S, Dahari H, Chayama K. SAT-164-Characterization of HBV kinetics during infection and treatment in primary human hepatocytes Journal of Hepatology. 70: e702. DOI: 10.1016/S0618-8278(19)31399-4 |
0.408 |
|
| 2019 |
Kumar U, Ribeiro R, Uprichard S, Galasso M, Cypel M, Humar A, Cotler S, Dahari H, Feld J. FRI-226-Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients Journal of Hepatology. 70: e494-e495. DOI: 10.1016/S0618-8278(19)30971-5 |
0.523 |
|
| 2019 |
Shekhtman L, Cotler S, Uprichard S, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Vaillant A, Dahari H. FRI-168-Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling Journal of Hepatology. 70: e463. DOI: 10.1016/S0618-8278(19)30913-2 |
0.39 |
|
| 2018 |
Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, et al. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 30499631 DOI: 10.1111/Liv.14014 |
0.618 |
|
| 2018 |
Kumberger P, Durso-Cain K, Uprichard SL, Dahari H, Graw F. Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models. Viruses. 10. PMID 29673154 DOI: 10.3390/V10040200 |
0.402 |
|
| 2018 |
Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K. Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology (Baltimore, Md.). PMID 29572897 DOI: 10.1002/Hep.29891 |
0.445 |
|
| 2018 |
Aunins TR, Marsh KA, Subramanya G, Uprichard SL, Perelson AS, Chatterjee A. Intracellular hepatitis C modeling predicts infection dynamics and viral protein mechanisms. Journal of Virology. PMID 29563295 DOI: 10.1128/Jvi.02098-17 |
0.725 |
|
| 2018 |
Kumar U, Uchida T, Hailegiorgis A, Hiraga N, Walsh K, Imamura M, Koh C, Heller T, Glenn J, Uprichard S, Chayama K, Dahari H. Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling appraoch Journal of Hepatology. 68: S783. DOI: 10.1016/S0168-8278(18)31835-X |
0.368 |
|
| 2018 |
Hailegiorgis A, Ishida Y, Imamura M, Hiraga N, Tateno C, Uprichard S, Chayama K, Dahari H. Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach Journal of Hepatology. 68: S782-S783. DOI: 10.1016/S0168-8278(18)31834-8 |
0.411 |
|
| 2018 |
Shekhtman L, Borochov N, Cotler S, Hershkovich L, Uprichard S, Al-Mahtab M, Bazinet M, Vaillant A, Dahari H. Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection Journal of Hepatology. 68: S508. DOI: 10.1016/S0168-8278(18)31264-9 |
0.424 |
|
| 2017 |
Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology Communications. 1: 288-292. PMID 29404459 DOI: 10.1002/hep4.1043 |
0.374 |
|
| 2017 |
Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K. HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. Plos One. 12: e0187409. PMID 29216198 DOI: 10.1371/Journal.Pone.0187409 |
0.632 |
|
| 2017 |
Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? Scientific Reports. 7: 10233. PMID 28860456 DOI: 10.1038/S41598-017-09776-Z |
0.522 |
|
| 2017 |
Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Research. 144: 281-285. PMID 28673800 DOI: 10.1016/J.Antiviral.2017.06.019 |
0.649 |
|
| 2017 |
Malespin M, Benyashvili T, Uprichard SL, Perelson AS, Dahari H, Cotler SJ. Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. Therapeutic Advances in Gastroenterology. 10: 68-73. PMID 28286560 DOI: 10.1177/1756283X16672392 |
0.63 |
|
| 2017 |
Borochov N, Cotler S, Uprichard S, Al-Mahtab M, Bazinet M, Vaillant A, Dahari H. Nucleic acid polymer REP2139 monotherapy reveals a short halflife of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients Journal of Hepatology. 66: S264. DOI: 10.1016/S0168-8278(17)30840-1 |
0.467 |
|
| 2016 |
Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report. World Journal of Hepatology. 8: 858-62. PMID 27458506 DOI: 10.4254/Wjh.V8.I20.858 |
0.514 |
|
| 2016 |
DebRoy S, Hiraga N, Imamura M, Hayes CN, Akamatsu S, Canini L, Perelson AS, Pohl RT, Persiani S, Uprichard SL, Tateno C, Dahari H, Chayama K. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. Journal of Viral Hepatitis. PMID 27272497 DOI: 10.1111/Jvh.12551 |
0.646 |
|
| 2016 |
Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. Journal of Hepatology. PMID 26907973 DOI: 10.1016/S2055-6640(20)31122-5 |
0.617 |
|
| 2016 |
Gambato M, Canini L, Lens S, Graw F, Londoño M, Uprichard S, Mariño Z, Reverter E, Bartres C, González P, Cotler S, Forns X, Dahari H. Modeling Early HCV Kinetics to Individualize Direct Acting Antivirals Treatment Duration in Patients with Advanced Cirrhosis Journal of Hepatology. 64: S795. DOI: 10.1016/S0168-8278(16)01550-6 |
0.589 |
|
| 2016 |
Yurdaydin C, Borochov N, Kalkan C, DebRoy S, Karatayli E, Haynes-Williams V, Karatayli S, Canini L, Uprichard S, Bozdayi AM, Choong I, Cory D, Heller T, Cotler S, Idilman R, et al. Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication Journal of Hepatology. 64: S587. DOI: 10.1016/S0168-8278(16)01079-5 |
0.519 |
|
| 2015 |
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. The Lancet. Infectious Diseases. PMID 26189433 DOI: 10.1016/S1473-3099(15)00074-2 |
0.501 |
|
| 2015 |
Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H. Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. Journal of Virology. 89: 6551-61. PMID 25833046 DOI: 10.1128/Jvi.00016-15 |
0.771 |
|
| 2015 |
Uprichard SL, Sainz B. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment. Gut. 64: 690-1. PMID 25287483 DOI: 10.1136/Gutjnl-2014-308396 |
0.656 |
|
| 2015 |
Canini L, Koh C, Cotler S, Zhao X, Uprichard S, Haynes-Williams V, Winters M, Subramanya G, Cooper S, Pinto P, Wolff E, Bishop R, Than Han M, Kleiner D, Keskin O, et al. LP36 : Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling Journal of Hepatology. 62: S281-S282. DOI: 10.1016/S0168-8278(15)30190-2 |
0.461 |
|
| 2014 |
Barretto N, Uprichard SL. Hepatitis C virus Cell-to-cell Spread Assay. Bio-Protocol. 4. PMID 29104884 DOI: 10.21769/BioProtoc.1365 |
0.46 |
|
| 2014 |
Sabahi A, Uprichard SL, Wimley WC, Dash S, Garry RF. Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. Journal of Virology. 88: 10280-8. PMID 24991010 DOI: 10.1128/Jvi.00874-14 |
0.62 |
|
| 2014 |
Barretto N, Sainz B, Hussain S, Uprichard SL. Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. Journal of Virology. 88: 5050-61. PMID 24554660 DOI: 10.1128/Jvi.03241-13 |
0.66 |
|
| 2014 |
Uprichard SL. Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection. Hepatology (Baltimore, Md.). 59: 2043-6. PMID 24277664 DOI: 10.1002/Hep.26949 |
0.498 |
|
| 2013 |
Anthony K, Subramanya G, Uprichard S, Hammouda F, Saleh M. Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food Supplements. Antioxidants (Basel, Switzerland). 2: 23-36. PMID 26787620 DOI: 10.3390/Antiox2010023 |
0.608 |
|
| 2013 |
Lee H, Zhu T, Patel K, Zhang YY, Truong L, Hevener KE, Gatuz JL, Subramanya G, Jeong HY, Uprichard SL, Johnson ME. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes. Plos One. 8: e75144. PMID 24130685 DOI: 10.1371/Journal.Pone.0075144 |
0.485 |
|
| 2013 |
Guedj J, Dahari H, Uprichard SL, Perelson AS. The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert Review of Gastroenterology & Hepatology. 7: 397-9. PMID 23899277 DOI: 10.1586/17474124.2013.811050 |
0.645 |
|
| 2013 |
Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proceedings of the National Academy of Sciences of the United States of America. 110: 10777-82. PMID 23754414 DOI: 10.1073/Pnas.1301764110 |
0.784 |
|
| 2013 |
Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences of the United States of America. 110: 3991-6. PMID 23431163 DOI: 10.1073/Pnas.1203110110 |
0.674 |
|
| 2012 |
Yu X, Sainz B, Petukhov PA, Uprichard SL. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrobial Agents and Chemotherapy. 56: 6109-20. PMID 22948883 DOI: 10.1128/Aac.01413-12 |
0.669 |
|
| 2012 |
Hussain S, Barretto N, Uprichard SL. New hepatitis C virus drug discovery strategies and model systems. Expert Opinion On Drug Discovery. 7: 849-59. PMID 22861052 DOI: 10.1517/17460441.2012.711312 |
0.658 |
|
| 2012 |
Sainz B, Barretto N, Yu X, Corcoran P, Uprichard SL. Permissiveness of human hepatoma cell lines for HCV infection. Virology Journal. 9: 30. PMID 22273112 DOI: 10.1186/1743-422X-9-30 |
0.671 |
|
| 2012 |
Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nature Medicine. 18: 281-5. PMID 22231557 DOI: 10.1038/Nm.2581 |
0.785 |
|
| 2011 |
Dahari H, Barretto N, Sainz B, Guedj J, Perelson A, Uprichard S. 776 MODELING INTERFERON-ALPHA MEDIATED INHIBITION KINETICS OF INTRACELLULAR AND EXTRACELLULAR HCVRNA DURING HCV INFECTION IN VITRO Journal of Hepatology. 54: S312. DOI: 10.1016/S0168-8278(11)60778-2 |
0.41 |
|
| 2010 |
Tencate V, Sainz B, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepatic Medicine : Evidence and Research. 2010: 125-145. PMID 21331152 DOI: 10.2147/Hmer.S7193 |
0.653 |
|
| 2010 |
Uprichard SL. Hepatitis C virus experimental model systems and antiviral drug research. Virologica Sinica. 25: 227-45. PMID 20960298 DOI: 10.1007/S12250-010-3134-0 |
0.659 |
|
| 2010 |
Yu X, Uprichard SL. Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening. Current Protocols in Microbiology. Unit 17.5.. PMID 20812217 DOI: 10.1002/9780471729259.Mc1705S18 |
0.675 |
|
| 2010 |
Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, Yu X, Garry RF, Uprichard SL. The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology. 407: 110-9. PMID 20800257 DOI: 10.1016/J.Virol.2010.07.026 |
0.717 |
|
| 2010 |
Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. Journal of Virology. 84: 7513-22. PMID 20504927 DOI: 10.1128/Jvi.00200-10 |
0.365 |
|
| 2009 |
Sainz B, Barretto N, Uprichard SL. Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. Plos One. 4: e6561. PMID 19668344 DOI: 10.1371/Journal.Pone.0006561 |
0.65 |
|
| 2009 |
Yu X, Sainz B, Uprichard SL. Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrobial Agents and Chemotherapy. 53: 4311-9. PMID 19620334 DOI: 10.1128/Aac.00495-09 |
0.652 |
|
| 2009 |
Sainz B, TenCate V, Uprichard SL. Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. Virology Journal. 6: 103. PMID 19604376 DOI: 10.1186/1743-422X-6-103 |
0.665 |
|
| 2009 |
Li L, Oropeza CE, Sainz B, Uprichard SL, Gonzalez FJ, McLachlan A. Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha. Plos One. 4: e5489. PMID 19424486 DOI: 10.1371/Journal.Pone.0005489 |
0.481 |
|
| 2009 |
Dahari H, Sainz B, Perelson AS, Uprichard SL. Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. Journal of Virology. 83: 6383-90. PMID 19369346 DOI: 10.1128/Jvi.02612-08 |
0.508 |
|
| 2009 |
TenCate V, Sainz B, Uprichard SL. M1807 Development of a Novel Three-Dimensional Differentiated Huh7 Cell Culture System for the Study of HCV Infection Gastroenterology. 136: A-842. DOI: 10.1016/S0016-5085(09)63881-6 |
0.573 |
|
| 2008 |
Rothwangl KB, Manicassamy B, Uprichard SL, Rong L. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virology Journal. 5: 46. PMID 18355410 DOI: 10.1186/1743-422X-5-46 |
0.35 |
|
| 2006 |
Uprichard SL, Chung J, Chisari FV, Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. Virology Journal. 3: 89. PMID 17069661 DOI: 10.1186/1743-422X-3-89 |
0.664 |
|
| 2005 |
Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America. 102: 9294-9. PMID 15939869 DOI: 10.1073/Pnas.0503596102 |
0.67 |
|
| 2005 |
Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proceedings of the National Academy of Sciences of the United States of America. 102: 773-8. PMID 15640346 DOI: 10.1073/Pnas.0409028102 |
0.474 |
|
| 2003 |
Uprichard SL, Knipe DM. Conformational changes in the herpes simplex virus ICP8 DNA-binding protein coincident with assembly in viral replication structures. Journal of Virology. 77: 7467-76. PMID 12805446 DOI: 10.1128/Jvi.77.13.7467-7476.2003 |
0.34 |
|
| 2003 |
Uprichard SL, Wieland SF, Althage A, Chisari FV. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proceedings of the National Academy of Sciences of the United States of America. 100: 1310-5. PMID 12552098 DOI: 10.1073/Pnas.252773599 |
0.472 |
|
| 2002 |
Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. Journal of Virology. 76: 5646-53. PMID 11991993 DOI: 10.1128/Jvi.76.11.5646-5653.2002 |
0.4 |
|
| 1998 |
De Bruyn Kops A, Uprichard SL, Chen M, Knipe DM. Comparison of the intranuclear distributions of herpes simplex virus proteins involved in various viral functions Virology. 252: 162-178. PMID 9875326 DOI: 10.1006/Viro.1998.9450 |
0.356 |
|
| 1997 |
Uprichard SL, Knipe DM. Assembly of herpex simplex virus replication proteins at two distinct intranuclear sites Virology. 229: 113-125. PMID 9123852 DOI: 10.1006/Viro.1996.8430 |
0.392 |
|
| 1996 |
Uprichard SL, Knipe DM. Herpes simplex ICP27 mutant viruses exhibit reduced expression of specific DNA replication genes Journal of Virology. 70: 1969-1980. PMID 8627723 DOI: 10.1128/Jvi.70.3.1969-1980.1996 |
0.363 |
|
| 1996 |
Liptak LM, Uprichard SL, Knipe DM. Functional order of assembly of herpes simplex virus DNA replication proteins into prereplicative site structures Journal of Virology. 70: 1759-1767. PMID 8627698 DOI: 10.1128/Jvi.70.3.1759-1767.1996 |
0.37 |
|
| Show low-probability matches. |